Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Preferred Stock Liabilities (2018 - 2019)

10x Genomics' Preferred Stock Liabilities history spans 2 years, with the latest figure at $243.2 million for Q2 2019.

  • On a quarterly basis, Preferred Stock Liabilities changed N/A to $243.2 million in Q2 2019 year-over-year; TTM through Jun 2019 was $243.2 million, a N/A change, with the full-year FY2018 number at $243.2 million, up 53.55% from a year prior.
  • Preferred Stock Liabilities hit $243.2 million in Q2 2019 for 10x Genomics, roughly flat from $243.2 million in the prior quarter.
  • Over the last five years, Preferred Stock Liabilities for TXG hit a ceiling of $243.2 million in Q4 2018 and a floor of $208.3 million in Q3 2018.